BioNTech (BNTX.US) late-stage melanoma trial shows promising results
On July 30, BioNTech (BNTX.US) announced that the tumor mRNA vaccine BNT111+PD-1 achieved the primary endpoint of ORR in the treatment of advanced or metastatic melanoma patients who progressed after PD-1 treatment, and the results were significantly better than historical data. BioNTech and its partner Regeneron plan to present specific data at future medical meetings.
BioNTech has a wide range of tumor-related products, and tumor therapeutic vaccines are one of the key products. On the one hand, BioNTech has laid out personalized neoantigen mRNA vaccines (BNT122, mRNA-4157) like Moderna. On the other hand, BioNTech is actively developing fixed-antigen tumor mRNA vaccines, including HPV vaccine BNT113 and melanoma vaccine BNT111. In terms of clinical strategy, BioNTech's personalized neoantigen vaccines are mainly used for the adjuvant treatment of early tumors, to prevent postoperative recurrence, and fixed-antigen vaccines are used for the treatment of advanced tumors.